Vestmark Advisory Solutions Inc. Sells 6,348 Shares of DexCom, Inc. $DXCM

Vestmark Advisory Solutions Inc. trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 41.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,824 shares of the medical device company’s stock after selling 6,348 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $770,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in DexCom by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after acquiring an additional 925,882 shares during the last quarter. Jennison Associates LLC raised its position in shares of DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares during the period. Nuveen LLC bought a new stake in shares of DexCom in the first quarter valued at about $554,893,000. Finally, Raymond James Financial Inc. grew its position in DexCom by 21.8% during the first quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after buying an additional 601,088 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

DexCom stock opened at $54.84 on Tuesday. The firm has a market capitalization of $21.39 billion, a P/E ratio of 38.08, a P/E/G ratio of 1.43 and a beta of 1.40. The stock has a fifty day moving average price of $68.83 and a two-hundred day moving average price of $77.61. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity

In other news, COO Jacob Steven Leach acquired 18,200 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was bought at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This represents a 5.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. This trade represents a 5.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 9,331 shares of company stock valued at $652,085. Corporate insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent research reports. Morgan Stanley cut their price target on DexCom from $89.00 to $63.00 and set an “equal weight” rating for the company in a report on Monday. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Wall Street Zen raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Wells Fargo & Company set a $93.00 price objective on shares of DexCom and gave the stock an “overweight” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.